Table 1 Crude, age/sex standardised and Bayesian-weighted test-adjusted SARS-CoV-2 anti-spike protein IgG seroprevalence across the whole study duration.
From: Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya
Kenya population | All samples (%) | Sero-positive | Crude seroprevalence | Bayesian weighted, test-adjusted seroprevalencea | |||
|---|---|---|---|---|---|---|---|
% | 95% CI | % | 95% CI | ||||
Age | |||||||
15–24 years | 9,733,174 | 2763 (27.8) | 241 | 8.7 | 7.7–9.8 | 7.5 | 6.2–8.8 |
25–34 years | 7,424,967 | 3902 (39.3) | 379 | 9.7 | 8.8–10.7 | 8.5 | 7.2–9.8 |
35–44 years | 4,909,191 | 2261 (22.8) | 224 | 9.9 | 8.7–11.2 | 8.3 | 6.9–9.8 |
45–54 years | 3,094,771 | 794 (8.0) | 66 | 8.3 | 6.5–10.5 | 7.3 | 5.5–8.9 |
55–64 years | 1,988,062 | 202 (2.1) | 18 | 8.9 | 5.4–13.7 | 7.2 | 5.2–9.1 |
Sex | |||||||
Male | 13,388,243 | 8019 (80.8) | 762 | 9.5 | 8.9–10.2 | 8.4 | 7.2–9.5 |
Female | 13,761,922 | 1903 (19.2) | 166 | 8.7 | 7.5–10.1 | 7.4 | 5.9–8.9 |
Region | |||||||
Central | 3,452,213 | 606 (6.1) | 38 | 6.3 | 4.5–8.5 | 5.8 | 3.7–8.0 |
Coast | 1,671,097 | 1680 (16.9) | 137 | 8.2 | 6.9–9.6 | 7.2 | 5.6–8.9 |
Eastern/N. Eastern | 5,176,080 | 1482 (14.9) | 108 | 7.3 | 6.0–8.7 | 6.5 | 4.9–8.2 |
Mombasa | 792,072 | 1654 (16.7) | 239 | 14.4 | 12.8–16.2 | 13.8 | 11.7–16 |
Nairobi | 3,002,314 | 607 (6.1) | 107 | 17.6 | 14.7–20.9 | 16.7 | 13.4–20.2 |
Nyanza | 3,363,813 | 1433 (14.4) | 131 | 9.1 | 7.7–10.8 | 8.3 | 6.6–10.2 |
Rift Valley | 7,035,581 | 2138 (21.6) | 145 | 6.8 | 5.8–7.9 | 5.9 | 4.5–7.4 |
Western | 2,656,995 | 322 (3.3) | 23 | 7.1 | 4.6–10.5 | 6.6 | 3.9–9.7 |
National | 27,150,165 | 9922 (100) | 928 | 9.4 | 8.8–9.9 | 7.9 | 6.7–9.0 |
